CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
D-cycloserine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00591825
NCT00591825Phase 2Completed
CompareCT.gov

An fMRI Study Investigating the Effects of Acute D-cycloserine Administration on Brain Activations and Cognitive Functioning in Spider Phobia.

University of Kansas Medical Center·interventional·Posted Jan 11, 2008·Updated Jun 5, 2017

In Brief

A Phase 2 clinical trial evaluating D-cycloserine and Placebo for Phobias. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The research team hopes to use brain imaging and mental testing to learn more about specific phobias and the treatment of phobia. When given directly prior to therapy sessions, D-cycloserine has been shown to enhance the effects of therapy. This study hopes to identify reasons why D-cycloserine has this effect by measuring brain activity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPhobias
CountriesUnited States
CollaboratorsAmerican Psychological Foundation, American Psychological Association (APA)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2008
Enrollment StartMar 1, 2006
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 18.5 years ago

Interventions

D-cycloserinedrug

D-cycloserine

Placebodrug

Placebo